Gogsen Onalan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gogsen Onalan has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Hulusi Bulent Zeyneloglu
Department of Obstetrics and Gynecology, Baskent University School of Medicine, Ankara, Turkey
11 shared publications - Yusuf Aytac Tohma
Department of Obstetrics and Gynecology, Baskent University School of Medicine, Ankara, Turkey
9 shared publications Reside Onalan
Obstetrics and Gynecology, Zekai Tahir Burak Women's Education and Research Hospital, Ankara, Turkey
6 shared publications- Emre Günakan
Department of Obstetrics and Gynecology, Baskent University School of Medicine, Ankara, Turkey
5 shared publications - Belgin Selam
Department of Obstetrics and Gynecology, School of Medicine, Acibadem Mehmet Ali Aydinlar University, 34752 İstanbul, Turkey
4 shared publications Temel Ceyhan
4 shared publications
Latest Publications
- Open Access
- 15 October 2025
- Published by Galenos Yayinevi in Journal of the Turkish-German Gynecological Association
- Vol. 26 (4) , 297-303
Fertility sparing surgery for malignant ovarian sex-cord stromal tumors: long-term obstetric and oncologic outcomes
Fertility sparing surgery for malignant ovarian sex-cord stromal tumors: long-term obstetric and oncologic outcomes - Journal of the Turkish-German Gynecological Association
- 15 October 2025
- Published by Galenos Yayinevi in Journal of the Turkish-German Gynecological Association
- Vol. 26 (4) , 297-303
Open AccessFertility sparing surgery for malignant ovarian sex-cord stromal tumors: long-term obstetric and oncologic outcomes
Fertility sparing surgery for malignant ovarian sex-cord stromal tumors: long-term obstetric and oncologic outcomes - Journal of the Turkish-German Gynecological Association
- 6 April 2023
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 307 (6) , 1969-1974
Extending the culture of cleavage-stage embryos to the blastocyst stage after warming increases the chance of live birth: does it have a regenerative effect?
Purpose We aimed to evaluate the effect of extending the culture of cleavage-stage embryos to the blastocyst stage in vitrified–warmed cycles on pregnancy outcomes. Methods This is a retrospectively designed pilot study of a single center. All patients who applied for freeze-all cycle procedures during in vitro fertilization treatment were included in the study. Patients were classified into three subgroups. The embryos obtained were frozen at the cleavage or blastocyst stage. After a warming process, the cleavage-stage embryos were divided into two subgroups: the first group of embryos was transferred (vitrification day 3–embryo transfer (ET) day 3 (D3T3)) on the warming day; for the second group, the embryo culture was extended to the blastocyst stage (vitrification day 3–ET day 5 (after the extension of the embryo culture to the blastocyst stage), (D3T5)). Frozen blastocyst-stage embryos were transferred after warming (vitrification day 5–ET day 5 (D5T5)). Hormone replacement treatment was the only endometrial preparation regimen given during the embryo transfer cycle. The main outcome of the study was live birth rates. The clinical pregnancy rate and positive pregnancy test rate were determined as the secondary outcomes of the study. Results The study included a total of 194 patients. The positive pregnancy test rates (PPR) and clinical pregnancy rates (CPR) of the D3T3, D3T5, and D5T5 groups were 14.0% and 59.2%; 43.8% and 9.3%; and 56.3% and 39.6%, respectively (p < 0.001 and p < 0.001). The live birth rates (LBR) of patients in the D3T3, D3T5, and D5T5 groups were 7.0%, 44.7%, and 27.1%, respectively (p < 0.001). In subgroup analysis of patients with a poor number of 2PN embryos (defined as having < = 4 2PN embryos), the D3T5 group had significantly higher PPR (10.7%, 60.6%, 42.4%; p < 0.001), CPR (7.1%, 57.6%, 39.4%; p < 0.001), and LBR (3.6%, 39.4%, 21.2%; p: 0.001). Conclusion Extending the culture after warming to the blastocyst stage may be a better alternative than a cleavage-stage embryo transfer.
- 6 April 2023
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 307 (6) , 1969-1974
Extending the culture of cleavage-stage embryos to the blastocyst stage after warming increases the chance of live birth: does it have a regenerative effect?
Purpose We aimed to evaluate the effect of extending the culture of cleavage-stage embryos to the blastocyst stage in vitrified–warmed cycles on pregnancy outcomes. Methods This is a retrospectively designed pilot study of a single center. All patients who applied for freeze-all cycle procedures during in vitro fertilization treatment were included in the study. Patients were classified into three subgroups. The embryos obtained were frozen at the cleavage or blastocyst stage. After a warming process, the cleavage-stage embryos were divided into two subgroups: the first group of embryos was transferred (vitrification day 3–embryo transfer (ET) day 3 (D3T3)) on the warming day; for the second group, the embryo culture was extended to the blastocyst stage (vitrification day 3–ET day 5 (after the extension of the embryo culture to the blastocyst stage), (D3T5)). Frozen blastocyst-stage embryos were transferred after warming (vitrification day 5–ET day 5 (D5T5)). Hormone replacement treatment was the only endometrial preparation regimen given during the embryo transfer cycle. The main outcome of the study was live birth rates. The clinical pregnancy rate and positive pregnancy test rate were determined as the secondary outcomes of the study. Results The study included a total of 194 patients. The positive pregnancy test rates (PPR) and clinical pregnancy rates (CPR) of the D3T3, D3T5, and D5T5 groups were 14.0% and 59.2%; 43.8% and 9.3%; and 56.3% and 39.6%, respectively (p < 0.001 and p < 0.001). The live birth rates (LBR) of patients in the D3T3, D3T5, and D5T5 groups were 7.0%, 44.7%, and 27.1%, respectively (p < 0.001). In subgroup analysis of patients with a poor number of 2PN embryos (defined as having < = 4 2PN embryos), the D3T5 group had significantly higher PPR (10.7%, 60.6%, 42.4%; p < 0.001), CPR (7.1%, 57.6%, 39.4%; p < 0.001), and LBR (3.6%, 39.4%, 21.2%; p: 0.001). Conclusion Extending the culture after warming to the blastocyst stage may be a better alternative than a cleavage-stage embryo transfer.
- 23 March 2023
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 162 (2) , 711-717
Oncologic and obstetric outcomes of early‐stage epithelial ovarian cancer patients who underwent fertility‐sparing surgery: A retrospective study
Objective: This study aimed to assess the long‐term oncologic and obstetric outcomes of women with epithelial ovarian cancer who underwent fertility‐sparing surgery.Methods: A total of 68 patients observed between March 2007 and July 2021 were included in this retrospective study. Unilateral salpingo‐oophorectomy and uterine preservation with staging surgery were the main procedures for fertility‐sparing surgery. Disease‐free, overall survival, and obstetric outcomes were measured as primary outcomes.Results: The median age of the patients was 30.5 years. The median follow‐up time was 60.5 months. Disease recurrence occurred in 15 (22.1%) of the patients. Five‐year disease‐free survival and overall survival (OS) percentages were 75.6% and 83.3%, respectively, for all stages. The FIGO (International Federation of Gynecology & Obstetrics) stage was the only significant factor that affected OS (P = 0.001). Twenty‐three patients tried to conceive, and 15 (65.2%) patients became pregnant. Twelve (80%) pregnancies reached term and resulted in 15 live births. Chemotherapy administration and surgical intervention (cystectomy or unilateral salpingo‐oophorectomy) showed no difference in pregnancy results (P = 0.806 and P = 0.066, respectively).Conclusion: Fertility preservation is safe for invasive epithelial ovarian cancer at early stages for women in the reproductive era. Disease recurrence and OS results are similar to standard treatment at early stages with decent obstetric outcomes.
- 23 March 2023
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 162 (2) , 711-717
Oncologic and obstetric outcomes of early‐stage epithelial ovarian cancer patients who underwent fertility‐sparing surgery: A retrospective study
Objective: This study aimed to assess the long‐term oncologic and obstetric outcomes of women with epithelial ovarian cancer who underwent fertility‐sparing surgery.Methods: A total of 68 patients observed between March 2007 and July 2021 were included in this retrospective study. Unilateral salpingo‐oophorectomy and uterine preservation with staging surgery were the main procedures for fertility‐sparing surgery. Disease‐free, overall survival, and obstetric outcomes were measured as primary outcomes.Results: The median age of the patients was 30.5 years. The median follow‐up time was 60.5 months. Disease recurrence occurred in 15 (22.1%) of the patients. Five‐year disease‐free survival and overall survival (OS) percentages were 75.6% and 83.3%, respectively, for all stages. The FIGO (International Federation of Gynecology & Obstetrics) stage was the only significant factor that affected OS (P = 0.001). Twenty‐three patients tried to conceive, and 15 (65.2%) patients became pregnant. Twelve (80%) pregnancies reached term and resulted in 15 live births. Chemotherapy administration and surgical intervention (cystectomy or unilateral salpingo‐oophorectomy) showed no difference in pregnancy results (P = 0.806 and P = 0.066, respectively).Conclusion: Fertility preservation is safe for invasive epithelial ovarian cancer at early stages for women in the reproductive era. Disease recurrence and OS results are similar to standard treatment at early stages with decent obstetric outcomes.
- Open Access
- 10 March 2023
- Published by Taylor & Francis in Journal of Obstetrics and Gynaecology
- Vol. 43 (1) , 2186776
Granulocyte colony-stimulating factor in assisted reproductive technology treatment does not increase the risk of adverse perinatal outcomes in twin pregnancies
The aim of the study is to compare the perinatal outcomes of twin pregnancies resulting from assisted reproductive technology (ART) treatment in which granulocyte colony-stimulating factor (G-CSF) was used with those in which it was not. In this retrospective study, the clinical data of 122 dichorionic diamniotic twin pregnancies were reviewed. Pregnancies were divided into two groups, G-CSF-treated and non-G-CSF treated. Maternal age, gestational week at birth, oligohydramnios, gestational hypertension, pre-eclampsia, preterm birth, first-trimester bleeding, gestational diabetes, rupture of membrane, foetal congenital anomalies, admission to the neonatal intensive care unit, birth weight (BW), small for gestational age, BW discordance, Apgar score and placental weight were compared between the groups.
- 10 March 2023
- Published by Taylor & Francis in Journal of Obstetrics and Gynaecology
- Vol. 43 (1) , 2186776
Open AccessGranulocyte colony-stimulating factor in assisted reproductive technology treatment does not increase the risk of adverse perinatal outcomes in twin pregnancies
The aim of the study is to compare the perinatal outcomes of twin pregnancies resulting from assisted reproductive technology (ART) treatment in which granulocyte colony-stimulating factor (G-CSF) was used with those in which it was not. In this retrospective study, the clinical data of 122 dichorionic diamniotic twin pregnancies were reviewed. Pregnancies were divided into two groups, G-CSF-treated and non-G-CSF treated. Maternal age, gestational week at birth, oligohydramnios, gestational hypertension, pre-eclampsia, preterm birth, first-trimester bleeding, gestational diabetes, rupture of membrane, foetal congenital anomalies, admission to the neonatal intensive care unit, birth weight (BW), small for gestational age, BW discordance, Apgar score and placental weight were compared between the groups.
- 8 March 2022
- Published by Taylor & Francis in Journal of Obstetrics and Gynaecology
- Vol. 42 (6) , 1-6
Diet and pravastatin administration prior to in vitro fertilization treatment may improve pregnancy outcome in women with dyslipidemia
In this study, we aimed to identify whether using statins may increase the chance of pregnancy in In Vitro Fertilisation / Intra-Cytoplasmic Sperm Injection (IVF/ICSI) patients with hyperlipidaemia. Therefore, in this retrospective cohort study, 70 patients constituted the study population and all patients were managed by lipid lowering diet. Ten mg pravastatin (pravachol DEVA, Istanbul, Turkey) was added to therapy in case of resistant hypercholesterolaemia after 15 days of the diet. Fifty-one patients were treated with diet only and the remaining nineteen patients were offered both diet and pravastatin. Clinical pregnancy rate was significantly better with the patients who used pravastatin (68.4% vs. 39.2%, p = .029). Ongoing pregnancy rates were 63.2% and 33.3% with pravastatin and diet only, respectively, which were statistically significant (p:.024). According to multivariate analysis, pravastatin use was found independently and statistically significant for clinical pregnancy and ongoing pregnancy rate after IVF/ICSI in patients with dyslipidemia (HR 3.79; 95% CI 1.31–10.97; p:.014 and HR 3.18; 95% CI 1.22–8.27; p:.018). When we analysed stratified data according to the AMH levels, we noticed that as AMH levels increased, the pregnancy rates increased; the most benefit from pravastatin was in the group with AMH levels >2 ng/mL.
- 8 March 2022
- Published by Taylor & Francis in Journal of Obstetrics and Gynaecology
- Vol. 42 (6) , 1-6
Diet and pravastatin administration prior to in vitro fertilization treatment may improve pregnancy outcome in women with dyslipidemia
In this study, we aimed to identify whether using statins may increase the chance of pregnancy in In Vitro Fertilisation / Intra-Cytoplasmic Sperm Injection (IVF/ICSI) patients with hyperlipidaemia. Therefore, in this retrospective cohort study, 70 patients constituted the study population and all patients were managed by lipid lowering diet. Ten mg pravastatin (pravachol DEVA, Istanbul, Turkey) was added to therapy in case of resistant hypercholesterolaemia after 15 days of the diet. Fifty-one patients were treated with diet only and the remaining nineteen patients were offered both diet and pravastatin. Clinical pregnancy rate was significantly better with the patients who used pravastatin (68.4% vs. 39.2%, p = .029). Ongoing pregnancy rates were 63.2% and 33.3% with pravastatin and diet only, respectively, which were statistically significant (p:.024). According to multivariate analysis, pravastatin use was found independently and statistically significant for clinical pregnancy and ongoing pregnancy rate after IVF/ICSI in patients with dyslipidemia (HR 3.79; 95% CI 1.31–10.97; p:.014 and HR 3.18; 95% CI 1.22–8.27; p:.018). When we analysed stratified data according to the AMH levels, we noticed that as AMH levels increased, the pregnancy rates increased; the most benefit from pravastatin was in the group with AMH levels >2 ng/mL.
- Open Access
- 31 December 2021
- Published by Acta Medica Alanya in Acta Medica Alanya
- Vol. 5 (3) , 289-293
Psychological conditions of patients whose infertility treatment was postponed due to the novel coronavirus pandemic lockdown
Aim: In this study, we planned to examine the psychological status of patients who were required to postpone their infertility treatment, by means of an online survey.Methods: Sixty patients who were in the follow-up were informed and an access link of online survey, which included questions about age, infertility status, Beck’s depression inventory(BDI) and Hamilton’s anxiety rating scale (HAM-A), were sent to them. Three different grouping systems were used based on (i-) age, (ii-) fertility treatment status and (iii-) indications for assisted reproduction technology treatment.Results: Mean scores of BDI and HAM-A in the whole group were 39.2(25-67) and 22.1(11-45), respectively. In the evaluation of survey scores according to indications of fertility treatment, BDI scores were between 34.2-44.7 and there was no statistical significance between the groups (p:0.182). HAM-A scores were between 18.7-38.0 and there was no statistical significance between the groups (p:0.185). In addition, there was no statistical significance between groups for BDI and HAM-A (p: 0.962 and 0.423, respectively) according to patients’ ART treatment status at the time the 2019-nCoV outbreak began in our country.Conclusion: Infertile patients will be more prone to depression and anxiety, and it should be noted that potential treatment postponements may increase their depression and anxiety.
- 31 December 2021
- Published by Acta Medica Alanya in Acta Medica Alanya
- Vol. 5 (3) , 289-293
Open AccessPsychological conditions of patients whose infertility treatment was postponed due to the novel coronavirus pandemic lockdown
Aim: In this study, we planned to examine the psychological status of patients who were required to postpone their infertility treatment, by means of an online survey.Methods: Sixty patients who were in the follow-up were informed and an access link of online survey, which included questions about age, infertility status, Beck’s depression inventory(BDI) and Hamilton’s anxiety rating scale (HAM-A), were sent to them. Three different grouping systems were used based on (i-) age, (ii-) fertility treatment status and (iii-) indications for assisted reproduction technology treatment.Results: Mean scores of BDI and HAM-A in the whole group were 39.2(25-67) and 22.1(11-45), respectively. In the evaluation of survey scores according to indications of fertility treatment, BDI scores were between 34.2-44.7 and there was no statistical significance between the groups (p:0.182). HAM-A scores were between 18.7-38.0 and there was no statistical significance between the groups (p:0.185). In addition, there was no statistical significance between groups for BDI and HAM-A (p: 0.962 and 0.423, respectively) according to patients’ ART treatment status at the time the 2019-nCoV outbreak began in our country.Conclusion: Infertile patients will be more prone to depression and anxiety, and it should be noted that potential treatment postponements may increase their depression and anxiety.
- Open Access
- 2 August 2021
- Published by Mebas Medikal Basin Yayin Ltd. Sti in Gynecology Obstetrics & Reproductive Medicine
- Vol. 27 (2) , 99-104
Placental Maspin Gene Expression Pattern May Be Used to Distinguish Between Preeclampsia and Intrauterine Growth Restriction
Objective: Maspin is one of the members of serin protease inhibitor superfamily, and acts as a tumor suppressor protein. Here we report maspin expression in placental tissues of preeclampsia or intrauterine growth retardation pregnancies.Study Design: Maspin expression level was analyzed by semi-quantitative RT-PCR method. For this purpose, placental tissue samples were obtained from pregnancies 13 with intrauterine growth retardation, and 6 with preeclampsia, and also 12 tissues from women without preeclampsia or intrauterine growth retardation history were included as controls. Results: Maspin expression was found to be 11-fold higher in placentas from preeclampsia patients than placentas from intrauterine growth retardation patients (p=0.036). However, there was no difference between preeclampsia and control groups (p=0.76), and intrauterine growth retardation and control groups (p=0.849).Conclusion: As far as we know this is the first study reporting expression level of maspin in placental tissues of pregnancies with intrauterine growth retardation. These findings support that molecular pathology between preeclampsia and IUGR might be different at the molecular level and maspin levels in the placenta may be used to differentiate preeclampsia from IUGR.
- 2 August 2021
- Published by Mebas Medikal Basin Yayin Ltd. Sti in Gynecology Obstetrics & Reproductive Medicine
- Vol. 27 (2) , 99-104
Open AccessPlacental Maspin Gene Expression Pattern May Be Used to Distinguish Between Preeclampsia and Intrauterine Growth Restriction
Objective: Maspin is one of the members of serin protease inhibitor superfamily, and acts as a tumor suppressor protein. Here we report maspin expression in placental tissues of preeclampsia or intrauterine growth retardation pregnancies.Study Design: Maspin expression level was analyzed by semi-quantitative RT-PCR method. For this purpose, placental tissue samples were obtained from pregnancies 13 with intrauterine growth retardation, and 6 with preeclampsia, and also 12 tissues from women without preeclampsia or intrauterine growth retardation history were included as controls. Results: Maspin expression was found to be 11-fold higher in placentas from preeclampsia patients than placentas from intrauterine growth retardation patients (p=0.036). However, there was no difference between preeclampsia and control groups (p=0.76), and intrauterine growth retardation and control groups (p=0.849).Conclusion: As far as we know this is the first study reporting expression level of maspin in placental tissues of pregnancies with intrauterine growth retardation. These findings support that molecular pathology between preeclampsia and IUGR might be different at the molecular level and maspin levels in the placenta may be used to differentiate preeclampsia from IUGR.
- 25 June 2021
- Published by Turkish Journal of Womens Health and Neonatology, University of Health Sciences in Türk Kadın Sağlığı ve Neonatoloji Dergisi
- Vol. 3 (2) , 27-32
Evaluation of the uterine cavity and fallopian tubes in one step in patients undergoing assisted reproductive technology treatment: Hysterosalpingofoam sonography (hyfosy) in combination with hysteroscopy
Aim: To report on the utilization of hysterosalpingo-foam sonography (HyFoSy) with hysteroscopic evaluation for selected patients undergoing Assisted Reproductive Technology Treatment (ART), whereby we aimed to assess the effectiveness of HyFoSy before hysteroscopy. Material and Method: This retrospective study included 36 infertile women referred to Baskent University’s Ankara Hospital Infertility Clinic in 2017-2019. HyFoSy was applied with hysteroscopy in one step for patients who had not previously been evaluated for tubal patency or who had to be re-evaluated. Results: Two patients were diagnosed with tubal obstruction by HyFoSy and were treated with hysteroscopic tubal catheterization, and tubal patency was obtained after this procedure. HyFoSy was applied in seven patients (19.49%) because their previous hysterosalpingography (HSG) reports were doubtful. Although previous HSG had shown tubal obstruction in three patients, the standard passage of the foam from the fallopian tubes to the abdominal cavity was observed when HyFoSy was applied. Conclusion: The one-step method that we apply in our clinic seems appropriate for both patients and clinicians because it speeds up the evaluation steps of the uterine cavity and fallopian tubes before the next ART attempt.
- 25 June 2021
- Published by Turkish Journal of Womens Health and Neonatology, University of Health Sciences in Türk Kadın Sağlığı ve Neonatoloji Dergisi
- Vol. 3 (2) , 27-32
Evaluation of the uterine cavity and fallopian tubes in one step in patients undergoing assisted reproductive technology treatment: Hysterosalpingofoam sonography (hyfosy) in combination with hysteroscopy
Aim: To report on the utilization of hysterosalpingo-foam sonography (HyFoSy) with hysteroscopic evaluation for selected patients undergoing Assisted Reproductive Technology Treatment (ART), whereby we aimed to assess the effectiveness of HyFoSy before hysteroscopy. Material and Method: This retrospective study included 36 infertile women referred to Baskent University’s Ankara Hospital Infertility Clinic in 2017-2019. HyFoSy was applied with hysteroscopy in one step for patients who had not previously been evaluated for tubal patency or who had to be re-evaluated. Results: Two patients were diagnosed with tubal obstruction by HyFoSy and were treated with hysteroscopic tubal catheterization, and tubal patency was obtained after this procedure. HyFoSy was applied in seven patients (19.49%) because their previous hysterosalpingography (HSG) reports were doubtful. Although previous HSG had shown tubal obstruction in three patients, the standard passage of the foam from the fallopian tubes to the abdominal cavity was observed when HyFoSy was applied. Conclusion: The one-step method that we apply in our clinic seems appropriate for both patients and clinicians because it speeds up the evaluation steps of the uterine cavity and fallopian tubes before the next ART attempt.
- 4 May 2021
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 37 (11) , 1000-1002
Dydrogesterone primed luteal phase stimulation may be better than follicular phase stimulation in patients with diminished ovarian reserve
In this study, we aimed to compare the efficacy of luteal phase stimulation (LPS) and follicular phase stimulation (FPS) in two separate menstrual cycles (2–5 months intervals) of the same patient, utilizing LPS with dydrogesteron only. This retrospective case control study was conducted with patients with diminished ovarian reserve (DOR) (Group 1) and infertile patients with Anti-Müllerian hormone >1.2 ng/mL (Group 2) undergoing two ovarian stimulations (FPS and LPS with dydrogesteron only) and two oocyte retrievals in two separate menstrual cycles (2–5 months intervals) in the Division of Reproductive Endocrinology and Infertility of Baskent University, Ankara, between April 2019 and December 2019. In group 1, the number of frozen embryos was significantly higher in LPS when compared to FPS; 1.71 vs. 0.54, (p < .001), respectively. In group 2, the number of frozen embryos was higher in LPS when compared to FPS (0.8 vs. 0.4) however the difference did not reach a statistical significance (p: 0.157). LPS may be beneficial especially in the patients with diminished ovarian reserve with follicular asynchronization in the menstrual onset. In addition, it should be kept in mind that dydrogesterone only may be used instead of gonadotropin-releasing hormone antagonist to prevent possible luteinizing hormone rise in LPS.
- 4 May 2021
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 37 (11) , 1000-1002
Dydrogesterone primed luteal phase stimulation may be better than follicular phase stimulation in patients with diminished ovarian reserve
In this study, we aimed to compare the efficacy of luteal phase stimulation (LPS) and follicular phase stimulation (FPS) in two separate menstrual cycles (2–5 months intervals) of the same patient, utilizing LPS with dydrogesteron only. This retrospective case control study was conducted with patients with diminished ovarian reserve (DOR) (Group 1) and infertile patients with Anti-Müllerian hormone >1.2 ng/mL (Group 2) undergoing two ovarian stimulations (FPS and LPS with dydrogesteron only) and two oocyte retrievals in two separate menstrual cycles (2–5 months intervals) in the Division of Reproductive Endocrinology and Infertility of Baskent University, Ankara, between April 2019 and December 2019. In group 1, the number of frozen embryos was significantly higher in LPS when compared to FPS; 1.71 vs. 0.54, (p < .001), respectively. In group 2, the number of frozen embryos was higher in LPS when compared to FPS (0.8 vs. 0.4) however the difference did not reach a statistical significance (p: 0.157). LPS may be beneficial especially in the patients with diminished ovarian reserve with follicular asynchronization in the menstrual onset. In addition, it should be kept in mind that dydrogesterone only may be used instead of gonadotropin-releasing hormone antagonist to prevent possible luteinizing hormone rise in LPS.
- 3 June 2020
- Published by Taylor & Francis in The Journal of Maternal-Fetal & Neonatal Medicine
- Vol. 35 (11) , 2041-2045
Gut dysbiosis may be associated with hyperemesis gravidarum
Purpose: In this study, we aimed to determine the frequency of different intestinal microorganisms of patients with normal pregnancies and HG and to compare these frequencies between the two groups. Materials and methods: This case-control study was carried out in Baskent University Department of Obstetrics and Gynecology and included 20 patients; 10 of whom had normal pregnancies and 10 of whom had HG. A stool flora scan was routinely planned for all patients. Transient and continuous fecal bacteria and fungal flora were analyzed. All data were evaluated statistically and their relationships with clinical condition were discussed. Results: The study group consisted of 20 pregnant women with a mean age of 31.5 years. All patients were nonsmokers and free of chronic diseases and of any medications. Aerobic and anaerobic bacteria groups, fungal colonies, and parasites were examined and bowel pH values were measured separately for each patient. Bacterial and fungal species outside the reference ranges were recorded for each patient. There was a statistically significant increase in Clostridium spp. (p:.01) and Candida spp. (p:.033) and a statistically significant decrease in Bifidobacterium spp.(p:.008) in patients with HG compared to women with normal pregnancies. There was a significant difference between the group with HG and the group with normal pregnancies in terms of flora dysbiosis (p:.001). Conclusion: Our results suggest that gut dysbiosis may be a factor in HG. The effect of the severity of gut dysbiosis on the disease may be the subject of future studies.
- 3 June 2020
- Published by Taylor & Francis in The Journal of Maternal-Fetal & Neonatal Medicine
- Vol. 35 (11) , 2041-2045
Gut dysbiosis may be associated with hyperemesis gravidarum
Purpose: In this study, we aimed to determine the frequency of different intestinal microorganisms of patients with normal pregnancies and HG and to compare these frequencies between the two groups. Materials and methods: This case-control study was carried out in Baskent University Department of Obstetrics and Gynecology and included 20 patients; 10 of whom had normal pregnancies and 10 of whom had HG. A stool flora scan was routinely planned for all patients. Transient and continuous fecal bacteria and fungal flora were analyzed. All data were evaluated statistically and their relationships with clinical condition were discussed. Results: The study group consisted of 20 pregnant women with a mean age of 31.5 years. All patients were nonsmokers and free of chronic diseases and of any medications. Aerobic and anaerobic bacteria groups, fungal colonies, and parasites were examined and bowel pH values were measured separately for each patient. Bacterial and fungal species outside the reference ranges were recorded for each patient. There was a statistically significant increase in Clostridium spp. (p:.01) and Candida spp. (p:.033) and a statistically significant decrease in Bifidobacterium spp.(p:.008) in patients with HG compared to women with normal pregnancies. There was a significant difference between the group with HG and the group with normal pregnancies in terms of flora dysbiosis (p:.001). Conclusion: Our results suggest that gut dysbiosis may be a factor in HG. The effect of the severity of gut dysbiosis on the disease may be the subject of future studies.